Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Lifarizine FA 是一种钠通道阻滞剂,可用于治疗神经系统疾病和心血管疾病,研究脑卒中。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,300 | 现货 | ||
5 mg | ¥ 2,900 | 现货 | ||
10 mg | ¥ 4,290 | 现货 | ||
25 mg | ¥ 6,850 | 现货 | ||
50 mg | ¥ 9,270 | 现货 | ||
100 mg | ¥ 12,500 | 现货 | ||
500 mg | ¥ 24,800 | 现货 |
产品描述 | Lifarizine FA is a sodium channel blocker used in the treatment of neurological disorders and cardiovascular diseases, study of stroke. |
体内活性 | Following the global ischaemic insult the rats were allowed to recover for 72 h before assessment of the damage, during which time one group of rats (n = 11) received 100 micrograms kg-1 lifarizine i.a. 5 min post-occlusion, 500 micrograms kg-1 lifarizine i.p. 15 min post-occlusion, and 500 micrograms kg-1 lifarizine i.p. twice daily for 72 h. A second group of rats (n = 12) was treated with appropriate volumes of vehicle (0.4 ml kg-1 i.a. and 2 ml kg-1 i.p.) at identical time points. The dosing regimen of lifarizine gave reduced damage in the hippocampal CA1 sub-field (4.1 +/- 0.3 to 2.8 +/- 0.6) and striatum (1.7 +/- 0.3 to 1.2 +/- 0.3) and significant neuroprotection in the anterior cortex (2.0 +/- 0.2 to 1.2 +/- 0.2; p < 0.05), thalamus (1.5 +/- 0.2 to 0.8 +/- 0.2; p < 0.01), posterior cortex (1.5 +/- 0.2 to 1.0 +/- 0.2; p < 0.05) and cerebellar brain stem (0.9 +/- 0.2 to 0.4 +/- 0.1; p < 0.01). The overall mean brain score was significantly reduced (from 1.5 +/- 0.1 to 0.9 +/- 0.2). These data show that the newly modified 2-vessel occlusion model produced a quantifiable level of ischaemic damage and that the novel agent lifarizine is neuroprotective in the model.[4] |
别名 | Lifarizine FA(119514-66-8 Free base) |
分子量 | 482.62 |
分子式 | C30H34N4O2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 55 mg/mL (113.96 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.072 mL | 10.3601 mL | 20.7202 mL | 51.8006 mL |
5 mM | 0.4144 mL | 2.072 mL | 4.144 mL | 10.3601 mL | |
10 mM | 0.2072 mL | 1.036 mL | 2.072 mL | 5.1801 mL | |
20 mM | 0.1036 mL | 0.518 mL | 1.036 mL | 2.59 mL | |
50 mM | 0.0414 mL | 0.2072 mL | 0.4144 mL | 1.036 mL | |
100 mM | 0.0207 mL | 0.1036 mL | 0.2072 mL | 0.518 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Lifarizine FA Membrane transporter/Ion channel Sodium Channel Lifarizine FA(119514-66-8 Free base) Inhibitor inhibitor inhibit